Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kazia Therapeutics ( (KZIA) ) has shared an update.
On July 25, 2025, Kazia Therapeutics Limited entered into an At the Market Offering Agreement with Rodman & Renshaw LLC to offer and sell American Depositary Shares (ADSs) worth up to $1,906,196. This strategic move aims to raise funds for general corporate purposes, including research, clinical development, and potential acquisitions. The agreement allows flexibility in sales, with Rodman acting as the sales agent, and highlights Kazia’s efforts to strengthen its financial position and support its ongoing development activities.
The most recent analyst rating on (KZIA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is a biotechnology company based in Sydney, Australia, focused on developing innovative cancer therapies. The company is involved in the research and development of product candidates, including Paxalisib, which is being tested in combination with other therapies.
Average Trading Volume: 1,085,032
Technical Sentiment Signal: Sell
Current Market Cap: $11.13M
Find detailed analytics on KZIA stock on TipRanks’ Stock Analysis page.